- Home
- TYRA vs GSL Comparison
TYRA vs GSL Comparison
Compare TYRA & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- GSL
- Stock Information
- Founded
- TYRA 2018
- GSL 2007
- Country
- TYRA United States
- GSL Greece
- Employees
- TYRA N/A
- GSL N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- GSL Marine Transportation
- Sector
- TYRA Health Care
- GSL Consumer Discretionary
- Exchange
- TYRA Nasdaq
- GSL Nasdaq
- Market Cap
- TYRA 576.6M
- GSL 945.2M
- IPO Year
- TYRA 2021
- GSL 2006
- Fundamental
- Price
- TYRA $10.91
- GSL $27.72
- Analyst Decision
- TYRA Strong Buy
- GSL Strong Buy
- Analyst Count
- TYRA 7
- GSL 1
- Target Price
- TYRA $30.86
- GSL $30.00
- AVG Volume (30 Days)
- TYRA 357.8K
- GSL 333.0K
- Earning Date
- TYRA 08-06-2025
- GSL 08-04-2025
- Dividend Yield
- TYRA N/A
- GSL 7.58%
- EPS Growth
- TYRA N/A
- GSL 20.64
- EPS
- TYRA N/A
- GSL 10.54
- Revenue
- TYRA N/A
- GSL $715,232,000.00
- Revenue This Year
- TYRA N/A
- GSL $3.22
- Revenue Next Year
- TYRA N/A
- GSL N/A
- P/E Ratio
- TYRA N/A
- GSL $2.65
- Revenue Growth
- TYRA N/A
- GSL 3.83
- 52 Week Low
- TYRA $6.42
- GSL $17.73
- 52 Week High
- TYRA $29.60
- GSL $28.08
- Technical
- Relative Strength Index (RSI)
- TYRA 62.87
- GSL 66.65
- Support Level
- TYRA $9.93
- GSL $26.80
- Resistance Level
- TYRA $10.49
- GSL $28.08
- Average True Range (ATR)
- TYRA 0.58
- GSL 0.57
- MACD
- TYRA 0.11
- GSL 0.06
- Stochastic Oscillator
- TYRA 97.66
- GSL 86.31
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.